期刊
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
卷 2016, 期 -, 页码 -出版社
HINDAWI LTD
DOI: 10.1155/2016/8565907
关键词
-
资金
- National Natural Science Foundation of China [81273741]
- Capital Clinical Medicine Application Characteristic Project of Beijing Science and Technology Committee [Z131107002213152]
- Scientific Research Common Program of Beijing Municipal Commission of Education [KM201311420084]
- Basic Clinical Cooperation Projects of Capital Medical University [13JL86]
We systematically assess the current clinical evidence of Gualouxiebaibanxia (GLXBBX) decoction for the treatment of angina pectoris (AP). We included RCTs testing GLXBBX against conventional drugs and GLXBBX combined with conventional drugs versus conventional drugs. 19 RCTs involving 1730 patients were finally identified, and the methodological quality was evaluated as generally low. The results of the meta-analysis showed that GLXBBX alone had significant effect on improving angina symptoms (RR: 1.24, 95% CI 1.14 to 1.35; P < 0.00001), ECG(RR: 1.28 [1.13, 1.44]; P < 0.0001), and HDL-C (MD: 0.56 [0.54, 0.58]; P < 0.00001) compared with anti-arrhythmic drugs. A significant improvement in angina symptoms (RR: 1.17 [1.12, 1.22]; P < 0.00001) and ECG (RR = 1.22; 95% CI = [1.14, 1.30]; P < 0.00001) was observed for GLXBBX plus conventional drugs when compared with conventional drugs. Eight trials reported adverse events without serious adverse effects. GLXBBX appears to have beneficial effects on improvement of ECG and reduction of angina symptoms in participants with AP. However, the evidence remains weak due to the poor methodological quality of the included studies. More rigorous trials are needed to confirm the results.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据